Cover Image
市場調查報告書

高活性療效原料藥 (HPAPI) 市場分析:產品,製造者,藥品類型,適應領域,各地區的市場預測

High Potency Active Pharmaceutical Ingredients (APIs) Market Analysis By Product (Synthetic, Biotech), Manufacturer (In-house, Outsourced), Drug Type, Therapeutic Application (Oncology, Hormonal, Glaucoma, Others), And Segment Forecasts, 2014 - 2025

出版商 Grand View Research, Inc. 商品編碼 344193
出版日期 內容資訊 英文 85 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
高活性療效原料藥 (HPAPI) 市場分析:產品,製造者,藥品類型,適應領域,各地區的市場預測 High Potency Active Pharmaceutical Ingredients (APIs) Market Analysis By Product (Synthetic, Biotech), Manufacturer (In-house, Outsourced), Drug Type, Therapeutic Application (Oncology, Hormonal, Glaucoma, Others), And Segment Forecasts, 2014 - 2025
出版日期: 2017年07月10日 內容資訊: 英文 85 Pages
簡介

本報告提供高活性療效原料藥 (HPAPI)的全球市場的相關調查,整體市場趨勢,各產品、製造者、藥品類型、適應領域、地區的詳細趨勢,市場規模的變化與預測,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業簡介等系統性資訊。

第1章 調查手法

第2章 摘要整理

第3章 高活性療效原料藥 (HPAPI) 市場趨勢

  • 市場區隔及市場範圍
  • 市場的推動要素
  • 市場阻礙因素
  • 市場機會
  • SWOT分析
  • 波特的五力分析

第4章 高活性療效原料藥 (HPAPI) 市場:各產品

  • 市場趨勢分析
  • 合成HPAPI
  • 生物科技HPAPI

第5章 高活性療效原料藥 (HPAPI) 市場:各製造廠商

  • 市場趨勢分析
  • 自家公司製造
  • 外包

第6章 高活性療效原料藥 (HPAPI) 市場:各藥品類型

  • 市場趨勢分析
  • 首發醫藥品
  • 學名藥

第7章 高活性療效原料藥 (HPAPI) 市場:各適應領域

  • 市場趨勢分析
  • 癌症
  • 內分泌疾病
  • 青光眼
  • 其他

第8章 高活性療效原料藥 (HPAPI) 市場:各地區

  • 各地區的市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第9章 競爭情形

  • 策略架構
  • 參與企業
  • 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 978-1-68038-563-2

The global HPAPIs market is expected to reach USD 34.8 billion by 2025, according to a new report by Grand View Research, Inc. Increasing number of new entrants producing fast relief therapeutics in emerging countries of India and China is anticipated to boost the demand for High potency active pharmaceutical ingredients (HPAPIs) over the forecast period.

In addition, supportive government regulations for commercialization and research and development of novel drug molecules are projected to drive the industry growth. Extensive capital investments required for development of production facility has lead to increase in contract manufacturing activities for HPAPIs during the forecast period.

Further Key Findings From the Study Suggest:

Synthetic route of High PotencyAPIs dominated the overall market in terms of revenue share as of 2016 owing to presence of large manufacturers producing these type of molecules

Biotech HPAPI segment is expected to be the fastest growing and is expected to grow at a lucrative growth ratedue torising demand for cancer drugs and fueling research and developmentactivities pertaining to it

Innovative drug market dominated the overall drug type in 2016. Generic drug segment is expected to be the fastest growing segment. The factors attributing to its growth are patent expiration of various drugs and increasing demand for the cancer treatment

Contact outsourcing segment is anticipated to show lucrative growth as major pharmaceuticals are focused on rigorous research and development activities for new drug development

Oncology segment heldlargest revenue share as of 2016, due to increasing demand for anti-cancerous drugs

North America HPAPIs market held the largest market share as of 2016. Growing prevalence of chronic disease patients, and established research and development infrastructure for novel drug development are factors supporting to major share of this market

Patent expiration of major drugs in North American and European countries is anticipated to fuel market growth

Asia Pacific regional market is expected to register significant growth owing to growing investments in biotechnology sector and rapidly growing oncology market

The key players in the HPAPI market includeBristol-Myers Squibb, Sigma-Aldrich Corporation, Pfizer Incand Lonza among others

Extensive research and development activities carried out by market participants is also expected to augment the market growth

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Country wise market: Base estimates
    • 1.1.1 Global market: CAGR calculation
    • 1.1.2 Region based segment share calculation
  • 1.2 Research Scope & Assumptions
  • 1.3 List of Data Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 HPAPI Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
  • 3.2 Market Driver Analysis
    • 3.2.1 Rise in prevalence of cancer and global anti-cancer market
    • 3.2.2 Growth of Targeted Therapy Approach
    • 3.2.3 Increasing application of HPAPI
  • 3.3 Market Restraint Analysis
    • 3.3.1 Large investments and very stringent safety and handling specifications associated with production of HPAPI
  • 3.4 Key Opportunities Prioritized
    • 3.4.1 Key opportunities prioritized, by product
  • 3.5 HPAPI - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.6 Industry Analysis - Porter's

Chapter 4 HPAPI Market: Product Estimates & Trend Analysis

  • 4.1 HPAPI Market: Product Movement Analysis
  • 4.2 Synthetic
    • 4.2.1 Synthetic market, 2014 - 2025 (USD Million)
  • 4.3 Biotech
    • 4.3.1 Biotech market, 2014 - 2025 (USD Million)

Chapter 5 HPAPI Market: Manufacturer Estimates & Trend Analysis

  • 5.1 HPAPI Market: Manufacturer Movement Analysis
  • 5.2 In-house
    • 5.2.1 In-house market, 2014 - 2025 (USD Million)
  • 5.3 Outsourced
    • 5.3.1 Outsourced market, 2014 - 2025 (USD Million)

Chapter 6 HPAPI Market: Drug Type Estimates & Trend Analysis

  • 6.1 HPAPI Market: Drug Type Movement Analysis
  • 6.2 Innovative
    • 6.2.1 Innovative market, 2014 - 2025 (USD Million)
  • 6.3 Generic
    • 6.3.1 Generic market, 2014 - 2025 (USD Million)

Chapter 7 HPAPI Market: Therapeutic Application Estimates & Trend Analysis

  • 7.1 HPAPI Market: Therapeutic Application Movement Analysis
  • 7.2 Oncology
    • 7.2.1 Oncology market, 2014 - 2025 (USD Million)
  • 7.3 Hormonal
    • 7.3.1 Hormonal market, 2014 - 2025 (USD Million)
  • 7.4 Glaucoma
    • 7.4.1 Glaucoma market, 2014 - 2025 (USD Million)
  • 7.5 Others
    • 7.5.1 Others market, 2014 - 2025 (USD Million)

Chapter 8 HPAPI Market: Regional Estimates & Trend Analysis, by Product, Manufacturer, Drug Type, and Therapeutic Application

  • 8.1 HPAPI Market Share by Region, 2016& 2025
  • 8.2 North America
    • 8.2.1 North America HPAPI market, by country, 2014 - 2025 (USD Million)
    • 8.2.2 North America HPAPI market, by product, 2014 - 2025 (USD Million)
    • 8.2.3 North America HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
    • 8.2.4 North America HPAPI market, by drug type, 2014 - 2025 (USD Million)
    • 8.2.5 North America HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
    • 8.2.6 U.S.
      • 8.2.6.1 U.S. HPAPI market, by product, 2014 - 2025 (USD Million)
      • 8.2.6.2 U.S. HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
      • 8.2.6.3 U.S. HPAPI market, by drug type, 2014 - 2025 (USD Million)
      • 8.2.6.4 U.S. HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
    • 8.2.7 Canada
      • 8.2.7.1 Canada HPAPI market, by product, 2014 - 2025 (USD Million)
      • 8.2.7.2 Canada HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
      • 8.2.7.3 Canada HPAPI market, by drug type, 2014 - 2025 (USD Million)
      • 8.2.7.4 Canada HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • 8.3 Europe
    • 8.3.1 Europe HPAPI market, by country, 2014 - 2025 (USD Million)
    • 8.3.2 Europe HPAPI market, by product, 2014 - 2025 (USD Million)
    • 8.3.3 Europe HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
    • 8.3.4 Europe HPAPI market, by drug type, 2014 - 2025 (USD Million)
    • 8.3.5 Europe HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
    • 8.3.6 Germany
      • 8.3.6.1 Germany HPAPI market, by product, 2014 - 2025 (USD Million)
      • 8.3.6.2 Germany HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.6.3 Germany HPAPI market, by drug type, 2014 - 2025 (USD Million)
      • 8.3.6.4 Germany HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
    • 8.3.7 UK
      • 8.3.7.1 UK HPAPI market, by product, 2014 - 2025 (USD Million)
      • 8.3.7.2 UK HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.7.3 UK HPAPI market, by drug type, 2014 - 2025 (USD Million)
      • 8.3.7.4 UK HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Asia Pacific HPAPI market, by country, 2014 - 2025 (USD Million)
    • 8.4.2 Asia Pacific HPAPI market, by product, 2014 - 2025 (USD Million)
    • 8.4.3 Asia Pacific HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
    • 8.4.4 Asia Pacific HPAPI market, by drug type, 2014 - 2025 (USD Million)
    • 8.4.5 Asia Pacific HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
    • 8.4.6 Japan
      • 8.4.6.1 Japan HPAPI market, by product, 2014 - 2025 (USD Million)
      • 8.4.6.2 Japan HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.6.3 Japan HPAPI market, by drug type, 2014 - 2025 (USD Million)
      • 8.4.6.4 Japan HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
    • 8.4.7 China
      • 8.4.7.1 China HPAPI market, by product, 2014 - 2025 (USD Million)
      • 8.4.7.2 China HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.7.3 China HPAPI market, by drug type, 2014 - 2025 (USD Million)
      • 8.4.7.4 China HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
    • 8.4.8 India
      • 8.4.8.1 India HPAPI market, by product, 2014 - 2025 (USD Million)
      • 8.4.8.2 India HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.8.3 India HPAPI market, by drug type, 2014 - 2025 (USD Million)
      • 8.4.8.4 India HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • 8.5 Latin America
    • 8.5.1 Latin America HPAPI market, by country, 2014 - 2025 (USD Million)
    • 8.5.2 Latin America HPAPI market, by product, 2014 - 2025 (USD Million)
    • 8.5.3 Latin America HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
    • 8.5.4 Latin America HPAPI market, by drug type, 2014 - 2025 (USD Million)
    • 8.5.5 Latin America HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
    • 8.5.6 Brazil
      • 8.5.6.1 Brazil HPAPI market, by product, 2014 - 2025 (USD Million)
      • 8.5.6.2 Brazil HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
      • 8.5.6.3 Brazil HPAPI market, by drug type, 2014 - 2025 (USD Million)
      • 8.5.6.4 Brazil HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
    • 8.5.7 Mexico
      • 8.5.7.1 Mexico HPAPI market, by product, 2014 - 2025 (USD Million)
      • 8.5.7.2 Mexico HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
      • 8.5.7.3 Mexico HPAPI market, by drug type, 2014 - 2025 (USD Million)
      • 8.5.7.4 Mexico HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • 8.6 MEA
    • 8.6.1 MEA HPAPI market, by country, 2014 - 2025 (USD Million)
    • 8.6.2 MEA HPAPI market, by product, 2014 - 2025 (USD Million)
    • 8.6.3 MEA HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
    • 8.6.4 MEA HPAPI market, by drug type, 2014 - 2025 (USD Million)
    • 8.6.5 MEA HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
    • 8.6.6 South Africa
      • 8.6.6.1 South Africa HPAPI market, by product, 2014 - 2025 (USD Million)
      • 8.6.6.2 South Africa HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
      • 8.6.6.3 South Africa HPAPI market, by drug type, 2014 - 2025 (USD Million)
      • 8.6.6.4 South Africa HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)

Chapter 9 Competitive Landscape

  • 9.1 Strategy Framework
  • 9.2 Market Participation
  • 9.3 Company Profiles
    • 9.3.1 Eli Lily and Company
      • 9.3.1.1 Company overview
      • 9.3.1.2 Financial performance
      • 9.3.1.3 Product benchmarking
      • 9.3.1.4 Strategic initiatives
    • 9.3.2 Novartis AG
      • 9.3.2.1 Company overview
      • 9.3.2.2 Financial performance
      • 9.3.2.3 Product benchmarking
      • 9.3.2.4 Strategic initiatives
    • 9.3.3 Bristol-Myers Squibb Company
      • 9.3.3.1 Company overview
      • 9.3.3.2 Financial performance
      • 9.3.3.3 Product benchmarking
      • 9.3.3.4 Strategic initiatives
    • 9.3.4 Roche Diagnostics Ltd.
      • 9.3.4.1 Company overview
      • 9.3.4.2 Financial performance
      • 9.3.4.3 Product benchmarking
      • 9.3.4.4 Strategic initiatives
    • 9.3.5 Sanofi
      • 9.3.5.1 Company overview
      • 9.3.5.2 Financial performance
      • 9.3.5.3 Product benchmarking
      • 9.3.5.4 Strategic initiatives
    • 9.3.6 Hospira, Inc.
      • 9.3.6.1 Company overview
      • 9.3.6.2 Financial performance
      • 9.3.6.3 Product benchmarking
      • 9.3.6.4 Strategic initiatives
    • 9.3.7 BASF SE
      • 9.3.7.1 Company overview
      • 9.3.7.2 Financial performance
      • 9.3.7.3 Product benchmarking
      • 9.3.7.4 Strategic initiatives
    • 9.3.8 Covidien plc
      • 9.3.8.1 Company overview
      • 9.3.8.2 Financial performance
      • 9.3.8.3 Product benchmarking
      • 9.3.8.4 Strategic initiatives
    • 9.3.9 Boehringer Ingelheim GmbH
      • 9.3.9.1 Company overview
      • 9.3.9.2 Financial performance
      • 9.3.9.3 Product benchmarking
      • 9.3.9.4 Strategic initiatives
    • 9.3.10 Merck & Co., Inc.
      • 9.3.10.1 Company overview
      • 9.3.10.2 Financial performance
      • 9.3.10.3 Product benchmarking
      • 9.3.10.4 Strategic initiatives
    • 9.3.11 Sigma Aldrich Corporation
      • 9.3.11.1 Company overview
      • 9.3.11.2 Financial performance
      • 9.3.11.3 Product benchmarking
      • 9.3.11.4 Strategic initiatives
    • 9.3.12 Bayer AG
      • 9.3.12.1 Company overview
      • 9.3.12.2 Financial performance
      • 9.3.12.3 Product benchmarking
      • 9.3.12.4 Strategic initiatives
    • 9.3.13 Carbogen Amcis AG
      • 9.3.13.1 Company overview
      • 9.3.13.2 Financial performance
      • 9.3.13.3 Product benchmarking
      • 9.3.13.4 Strategic initiatives
    • 9.3.14 Lonza
      • 9.3.14.1 Company overview
      • 9.3.14.2 Financial performance
      • 9.3.14.3 Product benchmarking
      • 9.3.14.4 Strategic initiatives
    • 9.3.15 Teva Pharmaceutical Industries Ltd.
      • 9.3.15.1 Company overview
      • 9.3.15.2 Financial performance
      • 9.3.15.3 Product benchmarking
      • 9.3.15.4 Strategic initiatives

List of Tables

  • TABLE 1 Country share estimation
  • TABLE 2 North America HPAPI market, by country, 2014 - 2025 (USD Million)
  • TABLE 3 North America HPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 4 North America HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 5 North America HPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 6 North America HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • TABLE 7 U.S. HPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 8 U.S. HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 9 U.S. HPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 10 U.S. HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • TABLE 11 Canada HPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 12 Canada HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 13 Canada HPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 14 Canada HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • TABLE 15 Europe HPAPI market, by country, 2014 - 2025 (USD Million)
  • TABLE 16 Europe HPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 17 Europe HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 18 Europe HPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 19 Europe HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • TABLE 20 Germany HPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 21 Germany HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 22 Germany HPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 23 Germany HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • TABLE 24 UK HPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 25 UK HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 26 UK HPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 27 UK HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • TABLE 28 Asia Pacific HPAPI market, by country, 2014 - 2025 (USD Million)
  • TABLE 29 Asia Pacific HPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 30 Asia Pacific HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 31 Asia Pacific HPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 32 Asia Pacific HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • TABLE 33 JapanHPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 34 JapanHPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 35 JapanHPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 36 Japan HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • TABLE 37 China HPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 38 China HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 39 China HPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 40 China HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • TABLE 41 India HPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 42 India HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 43 India HPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 44 India HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • TABLE 45 Latin America HPAPI market, by country, 2014 - 2025 (USD Million)
  • TABLE 46 Latin America HPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 47 Latin America HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 48 Latin America HPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 49 Latin America HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • TABLE 50 Brazil HPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 51 Brazil HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 52 Brazil HPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 53 Brazil HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • TABLE 54 Mexico HPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 55 Mexico HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 56 Mexico HPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 57 Mexico HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • TABLE 58 MEA HPAPI market, by country, 2014 - 2025 (USD Million)
  • TABLE 59 MEA HPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 60 MEA HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 61 MEA HPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 62 MEA research drug types market, by type, 2014 - 2025 (USD Million)
  • TABLE 63 MEA HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)
  • TABLE 64 South Africa HPAPI market, by product, 2014 - 2025 (USD Million)
  • TABLE 65 South Africa HPAPI market, by manufacturer, 2014 - 2025 (USD Million)
  • TABLE 66 South Africa HPAPI market, by drug type, 2014 - 2025 (USD Million)
  • TABLE 67 South Africa HPAPI market, by therapeutic application, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market summary
  • FIG. 2 Market trends & outlook
  • FIG. 3 Market segmentation & scope
  • FIG. 4 Market driver relevance analysis (Current & future impact)
  • FIG. 5 Market restraint relevance analysis (Current & future impact)
  • FIG. 6 Key opportunities prioritized, by product
  • FIG. 7 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 8 Porter's Five Forces Analysis
  • FIG. 9 HPAPI market, product outlook: Key takeaways
  • FIG. 10 HPAPI market: Product movement analysis
  • FIG. 11 Synthetic market, 2014 - 2025 (USD Million)
  • FIG. 12 Biotech market, 2014 - 2025 (USD Million)
  • FIG. 13 HPAPI market, manufacturer outlook: Key takeaways
  • FIG. 14 HPAPI market: manufacturer movement analysis
  • FIG. 15 In-house market, 2014 - 2025 (USD Million)
  • FIG. 16 Outsourced market, 2014 - 2025 (USD Million)
  • FIG. 17 HPAPI market, drug type outlook: Key takeaways
  • FIG. 18 HPAPI market: Drug type movement analysis
  • FIG. 19 Innovative market, 2014 - 2025 (USD Million)
  • FIG. 20 Generic market, 2014 - 2025 (USD Million)
  • FIG. 21 HPAPI market, therapeutic application outlook: Key takeaways
  • FIG. 22 HPAPI market: Therapeutic application movement analysis
  • FIG. 23 Oncology market, 2014 - 2025 (USD Million)
  • FIG. 24 Hormonal market, 2014 - 2025 (USD Million)
  • FIG. 25 Glaucoma market, 2014 - 2025 (USD Million)
  • FIG. 26 Others market, 2014 - 2025 (USD Million)
  • FIG. 27 Regional market place: Key takeaways
  • FIG. 28 Regional outlook, 2016 & 2025
  • FIG. 29 Strategy framework
  • FIG. 30 Market participation and categorization
Back to Top